- Global Pharma News & Resources

Nasal Antihistamines Market valuation is expected to increase from US$ 1.89 Billion in 2020 to over US$ 3.08 Billion by 2031

[250 Pages Report] According to a recent study by Future Market Insights (FMI), the nasal antihistamines market is expected to witness steady growth during the forecast period. The market valuation is expected to increase from US$ 1.89 Bn in 2020 to over US$ 3.08 Bn by 2031. This reflects a cumulative CAGR of around 3.1% over the forecast period (2021-2031).

Antihistamines are a class of medications that are often used to treat allergy symptoms. These medications are used to treat problems caused by an excess of histamine, a substance produced by the immune system. People who are allergic to pollen and other allergens are the most prevalent users of antihistamines. Sneezing, congestion, and itchy, runny nose can all be relieved with antihistamine sprays. They are available by prescription and include azelastine (Astelin, Astepro) and olopatadine (Patanase).

The global burden of respiratory diseases such as allergic rhinitis, chronic obstructive pulmonary disease, asthma has increased rapidly in the last three decades. In an article published in NCBI, it was reported that around 20–30 % of the Indian population suffers from allergic rhinitis and that 15 % develop asthma.

Due to this growing burden, there has been an increased adoption rate of nasal antihistamines in the form of nasal sprays and nasal drops, globally. The nasal antihistamines provide rapid and effective relief from the symptoms of allergic rhinitis. Thus, the growing number of allergic rhinitis cases will propel the growth of the nasal antihistamines market in the future.

Advancements in the field of nasal drug delivery have enabled the establishment of several non-invasive approaches for treatment. Various new products such as metered dose delivery systems, innovative odorless powders and sprays, preservative-free nasal sprays and others are key drivers that will expand this industry in the forecast period.

To remain ahead of your competitors, request for a sample –

FDA approvals of various nasal sprays to switch from prescription to OTC use has led to increased independence concerning self-administration of drugs, amongst patients who suffer from allergic rhinitis. Various additions by the manufacturers to the already available product lines, especially for AR are some of the techniques used by the manufacturers to increase product penetration amongst the population.

New product launches & approvals have emerged as key growth strategies adopted by the leading players in the nasal antihistamines market. Followed by this, the acquisition was the second most key strategy adopted by the industry players. By adopting these strategies, it helped the company to expand their regional presence as well as product offerings.

For instance, In December 2020, GlaxoSmithKline launched Otrivin Breathe clean, a saline wash with the moisturizing benefit of natural glycerine as a product for the symptomatic relief of allergic rhinitis.

Such developments not only strengthens the company’s existing portfolio but also help to increase their presence at the regional as well as global level, and helps companies to sustain the increasing competitive pressure.

“Growing prevalence of allergic rhinitis and resultant increase in adoption of nasal mode for drug delivery will drive the market growth in the next decade,” says the FMI Analyst

Key Takeaways from Nasal Antihistamines Market Study

  • By pProduct, nasal sprays accounted for the largest share of 89.0% in 2021 and are expected to continue to grow at the same trend during the forecast period.
  • By age group, adults accounted for the largest share in 2021 of the nasal antihistamines market and are expected to continue to grow at the same trend during the forecast period.
  • By distribution channel, the retail pharmacies segment is expected to account for the largest share of 41.0% in 2021 of the nasal antihistamines market and is expected to continue to grow at the same trend during the forecast period.
  • By region, East Asia held the largest share of 23.0% in 2021 of the nasal antihistamines market. The growing awareness regarding allergies and developing healthcare infrastructure are some of the factors that fuel the high market share of this region.

Scope of the Report

Attribute Details
Forecast Period 2021-2031
Historical Data Available for 2016-2020
Market Analysis USD Million for value
Key Regions Covered North America, Latin America, Europe, East Asia, South Asia, Oceania, and the Middle East & Africa
Key Countries Covered US, Canada, Germany, U.K., France, Italy, Spain, Poland, Russia, China, Japan, South Korea, India, Thailand, Malaysia, Vietnam, Indonesia, Australia, New Zealand, GCC Countries, Turkey, Northern Africa, and South Africa
Key Segments Covered Product, Age Group, Distribution Channel, Region
Key Companies Profiled
  • Bayer Healthcare LLC
  • Novartis AG
  • Glenmark Pharmaceuticals
  • GlaxoSmithKline
  • Sun Pharmaceuticals
  • Cipla
  • Merck & Co.
  • Viatris (Meda Pharmaceuticals)
  • Proctor & Gamble
  • Ascend Laboratories LLC (Alkem Laboratories)
  • Centaur Pharmaceuticals
  • J Pharmaceuticals
  • Alitair Pharmaceuticals
  • Sato Pharmaceuticals
Report Coverage Market Forecast, brand share analysis, competition Intelligence, DROT Analysis, Market Dynamics and Challenges and Strategic Growth Initiatives

Get a Tailored Made Report to Match Your requirements, Ask from Market Research Expert –

Who is Winning?Some of the leading manufacturers of the nasal antihistamines market are focusing on product launch collaboration and partnership strategies for global expansion objectives, thereby, enhancing their market presence.

  • In April 2021, Merck & Co. acquired Pandion Therapeutics, Inc which is a U.S. based clinical-stage biotechnology company for US $ 1.85 Bn. With this acquisition, Merck strategizes to identify and secure candidates with differentiated and potentially found characteristics for the clinical trials that would be required for their new product launches. This will ensure smooth conduction of clinical trials and thus help the company to expand their business.
  • In April 2020, Cipla receives final approval for a generic version of Proventil® HFA Inhalation Aerosol, from the United States FDA. With this approval, the company strengthened their presence in the US pharmaceutical market

The key market players covered by FMI include Bayer Healthcare LLC, Novartis International AG, Cipla, Glenmark Pharmaceuticals, GlaxoSmithKline, Sun Pharmaceuticals, Merck & Co., Centaur Pharmaceuticals, Viatris (Meda Pharmaceuticals), Proctor & Gamble, Ascend Laboratories LLC (Alkem Laboratories), J Pharmaceuticals, Alitair Pharmaceuticals and Sato Pharmaceuticals.

About Future Market Insights (FMI)
Future Market Insights (FMI) is a leading provider of market intelligence and consulting services, serving clients in over 150 countries. FMI is headquartered in Dubai, and has delivery centers in the UK, U.S. and India. FMI’s latest market research reports and industry analysis help businesses navigate challenges and make critical decisions with confidence and clarity amidst breakneck competition. Our customized and syndicated market research reports deliver actionable insights that drive sustainable growth. A team of expert-led analysts at FMI continuously tracks emerging trends and events in a broad range of industries to ensure that our clients prepare for the evolving needs of their consumers.

Future Market Insights,
1602-6 Jumeirah Bay X2 Tower,
Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates
For Sales Enquiries:
For Media Enquiries:

Editor Details

Last Updated: 15-Mar-2022